Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.3.5.1 (
succinate dehydrogenase
)
8,177
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Triggering receptor expressed on myeloid cells 2
(
TREM2
) is a transmembrane protein expressed on microglia within the brain. Several rare mutations in
TREM2
cause an early-onset form of neurodegeneration when inherited homozygously. Here we investigate how these mutations affect the intracellular transport of
TREM2
. We find that most pathogenic
TREM2
mutant proteins fail to undergo normal maturation in the Golgi complex and show markedly reduced cell-surface expression. Prior research has suggested that two such mutants are retained in the endoplasmic reticulum (ER), but we find, using a cell-free coat protein
complex II
(COPII) vesicle budding reaction, that mutant
TREM2
is exported efficiently from the ER. In addition, mutant
TREM2
becomes sensitive to cleavage by endoglycosidase D under conditions that inhibit recycling to the ER, indicating that it normally reaches a post-ER compartment. Maturation-defective
TREM2
mutants are also efficiently bound by a lectin that recognizes
O
-glycans added in the ER-Golgi intermediate compartment (ERGIC) and
cis
-Golgi cisterna. Finally, mutant
TREM2
accumulates in the ERGIC in cells depleted of COPI. These results indicate that efficient ER export is not sufficient to enable normal cell-surface expression of
TREM2
. Moreover, our findings suggest that the ERGIC may play an underappreciated role as a quality-control center for mutant and/or malformed membrane proteins.
...
PMID:Neurodegeneration-associated mutant TREM2 proteins abortively cycle between the ER and ER-Golgi intermediate compartment. 2876 30